Arsenite induces aquaglyceroporin 9 expression in murine livers.
Mice exposed to sodium arsenite show a dose-related accumulation of inorganic arsenic (iAs) and its methylated metabolites in the liver. While the accumulation of iAs forms increased linearly with dose in liver cells, a different pattern was observed in other tissues such as the brain and lung, as well as in the peripheral nerves of the rat. As such, trivalent iAs enters the cells, using aquaglyceroporin transporters to modulate cell arsenic accumulation and cytotoxicity. We investigated here if the dose-related accumulation of arsenic in the liver was related to the expression of aquaglyceroporin 9 (AQP9) in the same organ. CD1 male mice were treated with different concentrations (0, 2.5, 5 or 10mg/kg/day) of sodium arsenite during 1, 3 or 9 days. A significant dose-related, up-regulation of AQP9 mRNA and protein was observed and which was verified by immunohistochemistry in liver sections using specific antibodies. The increased transcription of AQP9 has been observed in fasting and diabetic rats, suggesting that this channel could play a role in the diabetogenic effect of arsenic.